NCT00303550已完成3 期
Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Arpida AG
- 试验地点
- 4
- 主要终点
- Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy
研究概览
简要总结
The study is now completed
详细描述
Primary Objective:
The primary objective of this study is to compare the clinical cure rates of iclaprim and linezolid at the test of cure (TOC) visit (7 to 14 days after the end of treatment).
Secondary Objectives:
The secondary objectives of this study are to compare iclaprim with linezolid regarding:
- Clinical efficacy at the end of study medication treatment;
- Time to resolution of systemic and local signs and symptoms of complicated skin and skin structure infection (cSSSI);
- Clinical outcome in the microbiologically evaluable (ME) population;
- Bacteriologic outcome in the ME population;
- Bacteriologic eradication rates of Baseline (BL) pathogens;
- Clinical outcome in the modified intent-to-treat (MITT) population;
- Bacteriologic outcome in the MITT population;
- Baseline in vitro susceptibility of isolated pathogens in the ME population; and
- Safety and tolerability of iclaprim treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen.
排除标准
- •Known or suspected hypersensitivity to any study medication or other related anti-infective medication
- •Any known or suspected condition or concurrent treatment contraindicated by the prescribing information
- •Previous enrollment in this study
- •Treatment with any investigational drug within 30 days before enrollment
结局指标
主要结局
Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy
次要结局
- Microbiological eradication rate at 7-14 days after end of therapy
- Safety evaluations conducted during the study
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections - ASSIST-1EUCTR2005-001548-21-LVArpida AG500
进行中（未招募）
不适用
Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections - Arpida’s Skin and Skin structure Infection STudy-2 (ASSIST-2)Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic streptococci (most commonly S. pyogenes and S. agalactiae), enterococcus spp., and viridans group streptococci.MedDRA version: 9.0Level: LLTClassification code 10040786EUCTR2005-003630-18-LVArpida AG500
进行中（未招募）
不适用
Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections - Arpida’s Skin and Skin structure Infection STudy-2 (ASSIST-2)Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic streptococci (most commonly S. pyogenes and S. agalactiae), enterococcus spp., and viridans group streptococci.MedDRA version: 8.1Level: HLTClassification code 10040786EUCTR2005-003630-18-LTArpida AG500
进行中（未招募）
不适用
Estudio fase III, multicéntrico, randomizado, controlado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y eficacia de Rituximab en combinación con metotrexato (MTX), en comparación con metotrexato sólo en pacientes con artritis reumatoide activa no tratados previamente con metotrexato”EUCTR2005-002395-15-ESF. Hoffmann-La Roche Ltd.853
未知
2 期
A Phase 2/3, multicenter, randomized, investigator-blinded study to evaluate the efficacy and safety of NK-104 versus Atorvastatin in Chinese patients with hypercholesterolaemiaJPRN-jRCT2080220211Kowa Co., Ltd.